The FDA has approved the first-of-its-kind device to treat atrial fibrillation (AF), a common heart rhythm disorder. The device, called the Bard Atrial Fibrillation Ablation System, uses radiofrequency energy to create small lesions in the heart that disrupt the electrical signals that cause AF.
AF is a condition in which the heart's upper chambers (atria) beat irregularly and rapidly. This can lead to blood clots, stroke, heart failure, and other serious complications. AF affects about 2.7 million Americans, and it is the most common heart arrhythmia in the United States.
The Bard Atrial Fibrillation Ablation System is a minimally invasive procedure that can be performed in the doctor's office or a hospital outpatient setting. The procedure takes about two hours, and patients typically go home the same day.
In clinical trials, the Bard Atrial Fibrillation Ablation System was shown to be effective in treating AF. The device was able to successfully convert AF to normal sinus rhythm in about 80% of patients. The device also showed a significant reduction in the risk of stroke and other complications associated with AF.
The approval of the Bard Atrial Fibrillation Ablation System is a significant development in the treatment of AF. The device offers a new, minimally invasive option for patients with AF who are not candidates for other treatments, such as surgery or medication.
Conclusion
The FDA approval of the Bard Atrial Fibrillation Ablation System is a welcome development for patients with AF. The device offers a new, minimally invasive option for patients who are not candidates for other treatments. The device is also expected to improve the quality of life for patients with AF by reducing the risk of stroke and other complications.
If you have AF, talk to your doctor about whether the Bard Atrial Fibrillation Ablation System is right for you.
Comments
Post a Comment